ExpreS2ion Biotech (Sweden) Top Management
| EXPRS2 Stock | SEK 5.17 0.09 1.77% |
ExpreS2ion Biotech employs about 14 people. The company is managed by 6 executives with a total tenure of roughly 33 years, averaging almost 5.0 years of service per executive, having 2.33 employees per reported executive. A leadership review of ExpreS2ion Biotech Holding matters because management quality often shapes how effectively strategy is translated into revenue growth, margins, and cash generation. Used properly, management analysis helps separate durable execution from results that may only reflect a supportive market cycle.
| Keith Alexander Insider Chief Officer |
| Lars Petersen Insider Medical Oncology |
ExpreS2ion |
Management Team Effectiveness
The company has return on total asset (ROA) of -55.13 % which means that on every $100 spent on assets, it lost $55.13. This is very low relative to industry peers. Similarly, it shows a return on equity (ROE) of -97.35 %, which implies that shareholder value decreased during the period.Outstanding Bonds
ExpreS2ion Biotech Holding may use bonds as part of its capital structure to fund operations, refinance liabilities, or support acquisitions and other long-duration investments. Maturity profile, refinancing windows, and coupon burden can all affect how resilient the capital structure looks in a weaker market.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Holders Distribution
For ExpreS2ion Biotech Holding, institutional participation can be supportive or destabilizing depending on whether large holders are building conviction or reducing exposure. The better interpretation comes from watching concentration, turnover, and changes in holder behavior instead of assuming institutional ownership is automatically bullish.
Workforce Comparison
ExpreS2ion Biotech Holding is rated second in number of employees among leading competitors. The total workforce of Biotechnology industry is currently estimated at about 149. ExpreS2ion Biotech holds roughly 14.0 in number of employees claiming about 9% of market share in Biotechnology space.
Benchmark Summation
Operator |
This analysis covers sixty-one data points across the selected time horizon. ExpreS2ion Biotech Price Series Summation is a cross summation of ExpreS2ion Biotech price series and its benchmark/peer.
Notable Stakeholders
Reviewing the stakeholders around ExpreS2ion Biotech can help investors understand which people or institutions may influence direction, governance, and strategic pressure. Used properly, stakeholder review helps investors stay aware of the people and incentives that may be shaping key decisions behind the scenes.
| Keith Alexander | Chief Officer | Profile | |
| Lars Petersen | Medical Oncology | Profile | |
| Mette Thorn | VP Devel | Profile | |
| Bent MSc | Chief Officer | Profile | |
| Mattis Ranthe | Chief Officer | Profile | |
| Max Sogaard | Dev Research | Profile |
Management Information & Data Sources
ExpreS2ion Biotech is a small-cap company in IT. Executive review focuses on insiders, senior management, and employee signals. Leadership review helps frame whether management actions match reported operating results. ExpreS2ion Biotech employs 14 people.
Reported values for ExpreS2ion Biotech Holding are derived from periodic company reporting and market reference feeds and then standardized by Macroaxis analytics. Refresh times depend on source availability. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Rifka Kats - Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Workforce efficiency at ExpreS2ion Biotech Holding can help investors judge how effectively labor resources are being converted into revenue and profit over time. The stronger interpretation compares these measures with sector norms because labor intensity varies meaningfully across industries.
ExpreS2ion Biotech Manpower Efficiency
Return on ExpreS2ion Biotech Manpower
| Revenue Per Employee | 873.9K | |
| Revenue Per Executive | 2M | |
| Net Loss Per Employee | 3.1M | |
| Net Loss Per Executive | 7.3M |
Popular Tools for ExpreS2ion Stock analysis
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |